248
Participants
Start Date
February 27, 2019
Primary Completion Date
December 4, 2024
Study Completion Date
December 11, 2026
CFZ533
s.c.
Placebo to CFZ533
s.c.
LYS006
p.o.
Placebo to LYS006
p.o.
MAS825
s.c.
Placebo to MAS825
s.c.
LOU064 25mg
p.o.
LOU064 100mg
p.o.
Placebo to LOU064
p.o.
VAY736
s.c.
Placebo to VAY736
s.c.
Novartis Investigative Site, Kopavogur
Novartis Investigative Site, Brussels
Novartis Investigative Site, Kobenhavn N V
Novartis Investigative Site, Roskilde
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Pécs
Novartis Investigative Site, Graz
Novartis Investigative Site, Prague
Novartis Investigative Site, Marseille
Novartis Investigative Site, Granada
Novartis Investigative Site, Schwerin
Novartis Investigative Site, Hamburg
Medical University of South Carolina MUSC ., Charleston
Advanced Medical Research, Sandy Springs
Park Avenue Dermatology, PA, Orange Park
University of South Florida, Tampa
Olympian Clinical Research ., Clearwater
Novartis Investigative Site, Las Palmas de Gran Canaria
Novartis Investigative Site, Bochum
Novartis Investigative Site, Valencia
Dawes Fretzin Clinical Rea Group, Indianapolis
Novartis Investigative Site, Manises
Novartis Investigative Site, Reims
NorthShore University Health System North Shore, Skokie
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Lyon
Novartis Investigative Site, Rouen
Novartis Investigative Site, Antony
Penn State Milton S Hershey Medical Center, Hershey
Novartis Investigative Site, Nice
Novartis Investigative Site, Budapest
Novartis Investigative Site, Szeged
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Groningen
Novartis Investigative Site, Sabadell
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY